Chronic hepatitis B virus (HBV) infection has been considered as the major cause of hepatocellular carcinoma (HCC). Hepatitis B virus X protein (HBx) has been reported to be oncogenic. The underlying mechanisms of HBV-related HCC are not fully understood, and the role played by the HBx protein in HBV induced carcinogenesis remains controversial. CDC42, a member of the Rho GTPase family, has been reported to be overexpressed in several different cancers, including HBV-related HCC. However, the specific role of CDC42 in HCC development remains unclear. Here, we investigated the cellular mechanisms by which CDC42 was responsible for the higher proliferation of HuH-7 cells mediated by HBx. We found that the expression level of CDC42 and its activity were significantly increased in HuH-7-HBx cells. The deficiency of CDC42 using the CRISPR/Cas9 system and inhibition by specific inhibitor CASIN led to the reduction of HBx-mediated proliferation. Furthermore, we observed that IQ Motif Containing GTPase Activating Protein 1 (IQGAP1), the downstream mediator of the CDC42 pathway, might be involved in the carcinogenesis induced by HBx. Therefore, the HBx/CDC42/IQGAP1 signaling pathway may potentially play an important role in HBx-mediated carcinogenesis.
The homologous cytokines
macrophage migration inhibitory factor
(MIF) and
d
-dopachrome tautomerase (
d
-DT or MIF2)
play key roles in cancers. Molecules binding to the MIF tautomerase
active site interfere with its biological activity. In contrast, the
lack of potent MIF2 inhibitors hinders the exploration of MIF2 as
a drug target. In this work, screening of a focused compound collection
enabled the identification of a MIF2 tautomerase inhibitor R110. Subsequent
optimization provided inhibitor
5d
with an IC
50
of 1.0 μM for MIF2 tautomerase activity and a high selectivity
over MIF.
5d
suppressed the proliferation of non-small
cell lung cancer cells in two-dimensional (2D) and three-dimensional
(3D) cell cultures, which can be explained by the induction of cell
cycle arrest via deactivation of the mitogen-activated protein kinase
(MAPK) pathway. Thus, we discovered and characterized MIF2 inhibitors
(
5d
) with improved antiproliferative activity in cellular
models systems, which indicates the potential of targeting MIF2 in
cancer treatment.
Macrophage migration inhibitory factor (MIF) is involved in protein-protein interactions that play key roles in inflammation and cancer.C urrent strategies to develop small molecule modulators of MIF functions are mainly restricted to the MIF tautomerase active site.H ere,w eu se this site to develop proteolysis targeting chimera (PROTAC)i no rder to eliminate MIF from its protein-protein interaction network. We report the first potent MIF-directed PROTAC, denoted MD13, which induced almost complete MIF degradation at low micromolar concentrations with aD C 50 around 100 nM in A549 cells. MD13 suppresses the proliferation of A549 cells, which can be explained by deactivation of the MAPK pathway and subsequent induction of cell cycle arrest at the G2/M phase. MD13 also exhibits antiproliferative effect in a3 D tumor spheroid model. In conclusion, we describe the first MIF-directed PROTAC(MD13)asaresearchtool, which also demonstrates the potential of PROTACs in cancer therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.